Secukinumab

CHEMBL1743068 Phase 4 Disetujui Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Injected under the skin, this biologic targets a specific immune protein called interleukin-17A that plays a central role in the inflammation behind psoriasis, psoriatic arthritis, and ankylosing spondylitis. Patients often see significant skin clearance and reduced joint symptoms within a few weeks of starting treatment.

Area Terapeutik

Dermatology Immunology Psoriasis Rheumatology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Injected under the skin, this biologic targets a specific immune protein called interleukin-17A that plays a central role in the inflammation behind psoriasis, psoriatic arthritis, and ankylosing spondylitis. Patients often see significant skin clearance and reduced joint symptoms within a few weeks of starting treatment.

Yes, Secukinumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743068. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Mencari informasi yang ramah bagi pasien?

Secukinumab di PillFYI

Data Cepat

Sinonim: 1

Tautan Eksternal

ChEMBL CHEMBL1743068

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.